1. Hims & Hers experienced a sell-off after Q4 2024 earnings due to profit-taking and weaker-than-expected EBITDA margins; 2. The company is projected to generate over $2 billion in revenues and $350 million in free cash flow in 2025; 3. Despite regulatory challenges and competition from Amazon Pharmacy, the long-term potential remains strong.